ATE536550T1 - Halbleiter nanokristalle enthaltende transfektibare mizellen - Google Patents

Halbleiter nanokristalle enthaltende transfektibare mizellen

Info

Publication number
ATE536550T1
ATE536550T1 AT09154683T AT09154683T ATE536550T1 AT E536550 T1 ATE536550 T1 AT E536550T1 AT 09154683 T AT09154683 T AT 09154683T AT 09154683 T AT09154683 T AT 09154683T AT E536550 T1 ATE536550 T1 AT E536550T1
Authority
AT
Austria
Prior art keywords
methods
semiconductor nanocrystals
gpcrs
micellars
transfectable
Prior art date
Application number
AT09154683T
Other languages
English (en)
Inventor
Marcel P Bruchez
R Hugh Daniels
Jennifer Dias
Larry C Mattheakis
Jianquan Liu
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26931860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE536550(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Application granted granted Critical
Publication of ATE536550T1 publication Critical patent/ATE536550T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5097—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving plant cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Botany (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT09154683T 2000-10-06 2001-10-05 Halbleiter nanokristalle enthaltende transfektibare mizellen ATE536550T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23867700P 2000-10-06 2000-10-06
US31255801P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
ATE536550T1 true ATE536550T1 (de) 2011-12-15

Family

ID=26931860

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01986346T ATE425457T1 (de) 2000-10-06 2001-10-05 Zellen mit spektraler signatur sowie verfahren zu ihrer herstellung und nutzung
AT09154683T ATE536550T1 (de) 2000-10-06 2001-10-05 Halbleiter nanokristalle enthaltende transfektibare mizellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01986346T ATE425457T1 (de) 2000-10-06 2001-10-05 Zellen mit spektraler signatur sowie verfahren zu ihrer herstellung und nutzung

Country Status (7)

Country Link
US (4) US20020155507A1 (de)
EP (2) EP2085781B2 (de)
AT (2) ATE425457T1 (de)
AU (1) AU2002226876A1 (de)
CA (1) CA2424817A1 (de)
DE (1) DE60137953D1 (de)
WO (1) WO2002029410A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
EP1414989A1 (de) * 2001-07-12 2004-05-06 Berlock APS Organometallische sonde
JP3683265B2 (ja) * 2002-05-28 2005-08-17 松下電器産業株式会社 ナノ粒子の製造方法及び該製造方法によって製造されたナノ粒子
US20040132173A1 (en) * 2002-08-28 2004-07-08 Kimon Angelides Optical fiber array device capable of simultaneously performing multiple functional assays
US7176036B2 (en) 2002-09-20 2007-02-13 Arrowhead Center, Inc. Electroactive microspheres and methods
EP1590656A1 (de) * 2003-01-24 2005-11-02 Plant Research International B.V. Identifikationsetikett bei pflanzen oder pflanzenteilen
US7723394B2 (en) * 2003-11-17 2010-05-25 Los Alamos National Security, Llc Nanocrystal/sol-gel nanocomposites
US7226953B1 (en) * 2003-11-17 2007-06-05 Los Alamos National Security, Llc Nanocrystal/sol-gel nanocomposites
US7846412B2 (en) * 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
US20050148100A1 (en) * 2003-12-30 2005-07-07 Intel Corporation Methods and devices for using Raman-active probe constructs to assay biological samples
US7226794B2 (en) * 2004-04-14 2007-06-05 Agilent Technologies, Inc. Surface-enhanced Raman spectroscopy for biosensor systems and methods for determining the presence of biomolecules
EP2400030B1 (de) * 2004-05-18 2016-01-20 The Board of Trustees of the Leland Stanford Junior University Detektion von Proteintranslokation durch Beta-Galactosidase-Reporter-Fragmentkomplementierung
CA2568168C (en) 2004-05-25 2016-07-05 Carlsberg A/S Identification of compounds modifying a cellular response
US7618778B2 (en) 2004-06-02 2009-11-17 Kaufman Joseph C Producing, cataloging and classifying sequence tags
JP4040610B2 (ja) * 2004-07-23 2008-01-30 キヤノン株式会社 物体の標識方法、該方法により標識を付された物体、ならびに付された標識の検出による物体の判別方法
JP2008514737A (ja) * 2004-09-09 2008-05-08 アプレーラ コーポレイション エネルギー移動検出系のためのジオキセタンナノ粒子アセンブリ、そのアセンブリを作製する方法、およびバイオアッセイにおいてそのアセンブリを使用する方法
FR2877571B1 (fr) * 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
WO2006055736A1 (en) * 2004-11-16 2006-05-26 Illumina, Inc. And methods and apparatus for reading coded microbeads
US20060148103A1 (en) * 2004-12-30 2006-07-06 Yin-Peng Chen Highly sensitive biological assays
US7397558B2 (en) * 2005-03-17 2008-07-08 Hewlett-Packard Development Company, L.P. Ordered array of nanoparticles for efficient nanoenhanced Raman scattering detection and methods of forming the same
US8845927B2 (en) * 2006-06-02 2014-09-30 Qd Vision, Inc. Functionalized nanoparticles and method
US9297092B2 (en) * 2005-06-05 2016-03-29 Qd Vision, Inc. Compositions, optical component, system including an optical component, devices, and other products
US8263417B2 (en) * 2006-01-04 2012-09-11 The Board Of Trustees Of The Leland Stanford Junior University Self-illuminating dot systems and methods of use thereof
US7226752B1 (en) * 2006-01-19 2007-06-05 Avago Technologies General Ip (Singapore) Pte. Ltd. Methods for detecting an analyte in a sample
US8849087B2 (en) * 2006-03-07 2014-09-30 Qd Vision, Inc. Compositions, optical component, system including an optical component, devices, and other products
WO2007120762A2 (en) * 2006-04-14 2007-10-25 Cambrios Technologies Corporation Fluorescent particles bound to multifunctional scaffolds and their uses
US9212056B2 (en) * 2006-06-02 2015-12-15 Qd Vision, Inc. Nanoparticle including multi-functional ligand and method
US20080003576A1 (en) * 2006-06-30 2008-01-03 Jingwu Zhang Assay platforms and detection methodology using surface enhanced Raman scattering (SERS) upon specific biochemical interactions
WO2008049034A1 (en) * 2006-10-17 2008-04-24 Zymera, Inc. System for assays of aminotranferase
US20100056391A1 (en) * 2006-12-22 2010-03-04 Trustees Of Princeton University Integrated screening assays and methods of use
US9557217B2 (en) * 2007-02-13 2017-01-31 Bti Holdings, Inc. Universal multidetection system for microplates
EP2126581B1 (de) * 2007-03-20 2014-07-09 Becton Dickinson and Company Assays unter verwendung von wirkstoffen für oberflächenverstärkte raman-spektroskopie
EP2207789B1 (de) * 2007-09-12 2014-06-11 QD Vision, Inc. Funktionalisierte nanopartikel und verfahren
CA2734895C (en) 2008-08-18 2014-06-17 Discoverx Corporation Receptor tyrosine kinase assays
US20100136551A1 (en) * 2008-10-10 2010-06-03 Hansang Cho Microfluidic platform and related methods and systems
US7879625B1 (en) 2008-12-03 2011-02-01 The United States Of America As Represented By The Secretary Of The Navy Preparation of SERS substrates on silica-coated magnetic microspheres
WO2010104600A1 (en) * 2009-03-13 2010-09-16 Oxazogen, Inc. Optical power limiting polymeric matrix
CA2777841C (en) 2009-11-02 2017-01-17 Francis M. Creighton Magnetomotive stator system and methods for wireless control of magnetic rotors
GB201005601D0 (en) 2010-04-01 2010-05-19 Nanoco Technologies Ltd Ecapsulated nanoparticles
US20130273561A1 (en) * 2010-10-29 2013-10-17 The Governing Council Of The University Of Toronto Lipid encapsulation of surface enhanced raman scattering (sers) nanoparticles
WO2012158832A2 (en) 2011-05-16 2012-11-22 Qd Vision, Inc. Method for preparing semiconductor nanocrystals
WO2013028253A1 (en) 2011-08-19 2013-02-28 Qd Vision, Inc. Semiconductor nanocrystals and methods
MY181697A (en) * 2012-03-30 2021-01-04 Johnson Matthey Plc Tracer and method of identifying tracer in product
US9883878B2 (en) 2012-05-15 2018-02-06 Pulse Therapeutics, Inc. Magnetic-based systems and methods for manipulation of magnetic particles
US10067149B2 (en) 2012-12-12 2018-09-04 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
BR112015013710B1 (pt) 2012-12-12 2022-08-09 Promega Corporation Métodos in vitro para detectar uma interação entre um agente bioativo e um alvo celular
HK1246160A1 (zh) 2015-05-28 2018-09-07 Nanobiotix 用作治疗性疫苗的纳米粒子
WO2017147407A1 (en) * 2016-02-25 2017-08-31 Board Of Regents, The University Of Texas System Compositions comprising composite nanocarriers and methods of making and uses thereof
US11918315B2 (en) 2018-05-03 2024-03-05 Pulse Therapeutics, Inc. Determination of structure and traversal of occlusions using magnetic particles
US20220057405A1 (en) * 2019-02-25 2022-02-24 Absorption Systems Llc Cells and methods for evaluating the activity of organic anion transporting polypeptide 2a1 (oatp2a1)
US12171443B1 (en) 2021-03-09 2024-12-24 Pulse Therapeutics, Inc. Magnetically controlled flow generation

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770380A (en) 1971-04-19 1973-11-06 Us Army Article and method for multiple immune adherence assay
US4011308A (en) 1974-01-04 1977-03-08 General Electric Company Method for surface immunological detection of biological particles by the use of tagged antibodies
US3876504A (en) 1974-06-10 1975-04-08 Early Warning Co Procedure for determination of antigens and antibodies and articles for use therewith
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4372745A (en) 1979-12-19 1983-02-08 Electro-Nucleonics, Inc. Chemical luminescence amplification substrate system for immunochemistry involving microencapsulated fluorescer
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (de) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Verfahren zum Verstellen des Übersetzungsverhältnisses eines stufenlosen Getriebes unter Anpassung der Beschleunigung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4743548A (en) 1984-09-25 1988-05-10 Calgene, Inc. Plant cell microinjection technique
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
EP0188256B1 (de) 1985-01-14 1991-08-21 NeoRx Metall-Radionuklid markiertes Protein für Diagnose und Therapie
US4722890A (en) 1985-08-27 1988-02-02 The United States Of America As Represented By The Department Of Health And Human Services Quantitative assay for human terminal complement cascade activation
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5068193A (en) 1985-11-06 1991-11-26 Calgene, Inc. Novel method and compositions for introducing alien DNA in vivo
US4795855A (en) 1985-11-14 1989-01-03 Joanne Fillatti Transformation and foreign gene expression with woody species
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5188958A (en) 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
US5565347A (en) 1986-06-10 1996-10-15 Calgene, Inc. Transformation and foreign gene expression with plant species
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5218112A (en) 1988-02-03 1993-06-08 Xoma Corporation Linking agents and methods
US5090914A (en) 1988-03-04 1992-02-25 Xoma Corporation Activated polymers and conjugates thereof
US5330746A (en) * 1988-05-03 1994-07-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dental varnish composition, and method of use
US5565346A (en) 1988-07-27 1996-10-15 Calgene, Inc. Transformation and regeneration system for legumes
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
EP0549692A4 (en) 1990-09-21 1993-08-25 Fred Hutchinson Cancer Research Center Protein sequence-specific oligonucleotide sequences
EP0555333B1 (de) 1990-10-19 1995-12-27 University Of Florida Künstliche virushüllen
US5252348A (en) 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
EP0572529A4 (de) 1991-02-21 1994-11-02 Gilead Sciences Inc Spezifisches aptamer für biomolekülen und verfahren zu dessen produktion.
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5534416A (en) * 1993-04-13 1996-07-09 Molecular Probes, Inc. Fluorescent viability assay using cyclic-substituted unsymmetrical cyanine dyes
DE69530553T2 (de) * 1994-05-13 2004-03-25 KURARAY CO., LTD, Kurashiki Medizinisches polymergel
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
JP2740153B2 (ja) * 1995-03-07 1998-04-15 エフ・ホフマン−ラ ロシユ アーゲー 混合ミセル
US6069296A (en) 1995-06-02 2000-05-30 Massachusetts Institute Of Technology Regulators of G-protein signalling
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
AU726749B2 (en) * 1995-08-10 2000-11-16 Kazunori Kataoka Block polymer having functional groups on its both ends
GB9609793D0 (en) 1996-05-10 1996-07-17 Ciba Geigy Ag Pigment compositions
US5874245A (en) 1996-05-16 1999-02-23 Takeda Chemical Industries, Ltd. Human G-protein coupled receptor (HIBCD07)
IL132941A0 (en) * 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US20030004123A1 (en) * 1997-06-26 2003-01-02 Boucher Richard C. Targeted gene transfer using G protein coupled receptors
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US5990479A (en) * 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6048615A (en) 1998-01-30 2000-04-11 E. I. Du Pont De Nemours And Company Filament having a trilobal cross-section and a trilobal void
US6210910B1 (en) * 1998-03-02 2001-04-03 Trustees Of Tufts College Optical fiber biosensor array comprising cell populations confined to microcavities
US6280934B1 (en) 1998-05-13 2001-08-28 Millennium Pharmaceuticals, Inc. Assay for agents which alter G-protein coupled receptor activity
US6036886A (en) * 1998-07-29 2000-03-14 Nanocrystals Technology L.P. Microemulsion method for producing activated metal oxide nanocrystals
EP1271154A3 (de) * 1998-09-18 2005-08-17 Massachusetts Institute Of Technology Biologische Verwendung von Halbleiter-Nanokristallen
CA2344478C (en) 1998-09-18 2010-03-30 Massachusetts Institute Of Technology Biological applications of semiconductor nanocrystals
US6617583B1 (en) * 1998-09-18 2003-09-09 Massachusetts Institute Of Technology Inventory control
US6251303B1 (en) * 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6306610B1 (en) * 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6114038A (en) * 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6261779B1 (en) * 1998-11-10 2001-07-17 Bio-Pixels Ltd. Nanocrystals having polynucleotide strands and their use to form dendrimers in a signal amplification system
US6235540B1 (en) * 1999-03-30 2001-05-22 Coulter International Corp. Semiconductor nanoparticles for analysis of blood cell populations and methods of making same
AU4701200A (en) * 1999-05-07 2000-11-21 Quantum Dot Corporation A method of detecting an analyte using semiconductor nanocrystals
MXPA02003284A (es) 1999-10-01 2002-10-04 Surromed Inc Metodo de manufactura de particulas coloidales cilindricas como codigos de nanobarras.
US7225082B1 (en) 1999-10-01 2007-05-29 Oxonica, Inc. Colloidal rod particles as nanobar codes
US6194213B1 (en) * 1999-12-10 2001-02-27 Bio-Pixels Ltd. Lipophilic, functionalized nanocrystals and their use for fluorescence labeling of membranes
EP1246607B1 (de) * 1999-12-30 2007-06-27 Dana-Farber Cancer Institute, Inc. Proteoliposomen, die ein integral membranprotein mit einer oder memhreren transmembrandomänen enthalten
US20030099940A1 (en) 2000-02-16 2003-05-29 Empedocles Stephen A. Single target counting assays using semiconductor nanocrystals
US6761877B2 (en) * 2000-02-18 2004-07-13 Biocrystal, Ltd. Functionalized encapsulated fluorescent nanocrystals
US6734420B2 (en) 2000-04-06 2004-05-11 Quantum Dot Corporation Differentiable spectral bar code methods and systems
US6838243B2 (en) * 2000-04-28 2005-01-04 Quantum Dot Corporation Methods and compositions for polynucleotide analysis using generic capture sequences
US6548264B1 (en) * 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
AU2002306500C1 (en) * 2001-02-16 2006-09-28 Cellgate, Inc. Transporters comprising spaced arginine moieties

Also Published As

Publication number Publication date
EP1327145A2 (de) 2003-07-16
EP2085781A1 (de) 2009-08-05
ATE425457T1 (de) 2009-03-15
WO2002029410A3 (en) 2003-01-30
EP2085781B2 (de) 2020-03-11
CA2424817A1 (en) 2002-04-11
DE60137953D1 (de) 2009-04-23
US20070148634A1 (en) 2007-06-28
US20040023261A1 (en) 2004-02-05
US20020155507A1 (en) 2002-10-24
WO2002029410A2 (en) 2002-04-11
EP2085781B1 (de) 2011-12-07
AU2002226876A1 (en) 2002-04-15
EP1327145B1 (de) 2009-03-11
US20160161496A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
ATE536550T1 (de) Halbleiter nanokristalle enthaltende transfektibare mizellen
DE69939945D1 (de) Verfahren zur isolierung von stammzellen
ATE408455T1 (de) Arrayplatten und verfahren zur herstellung von arrayplatten
ES2088470T3 (es) Ensayo de una etapa para recuento absoluto.
ATE490466T1 (de) Als interne funktionskontrolle in tests zum nachweis von seltenen zellen verwendete markierte zellen
CA2374735A1 (en) Encoding and decoding of array sensors utilizing nanocrystals
EP1399547A4 (de) VERFAHREN UND ZUSAMMENSETZUNGEN MIT i RENILLA /iGFP
DE60210406D1 (de) Erhöhung des durchsatzes in einem automatischen klinischen analysierer durch aufteilen von assays nach typ
WO2004012658A3 (en) Method and device for protein delivery into cells
DE60230672D1 (de) Nukleinsäureanreicherung
WO2005063817A3 (en) Methods for identifying functional antibodies
WO2002079490A3 (en) Bio-barcodes based on oligonucleotide-modified particles
WO2005021728A3 (en) Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
ATE266204T1 (de) ßFLOW-ZYTOMETRISCHERß VOLLBLUT- DENDRITZELLE- IMMUNFUNCTIONTEST
WO2002061387A3 (en) Open substrate platforms suitable for analysis of biomolecules
ATE421697T1 (de) Verfahren zur identifizierung von verbindungen, die transmembran-proteine beeinflussen
DE69622696D1 (de) Zellzählung durch einen immunoassay
DE60110407D1 (de) Reagenz zur bestimmung von blutplättchen-mikroteilchen
WO2004020597A3 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
DE60037007D1 (de) Angereicherte zentralnervensystem-zellpopulationen
IL162568A0 (en) fluorescent protein from aequorea coerulscens and uses thereof
DE69629976D1 (de) Typ I Prokollagen aminoterminales Propeptid, dessen Antikörper und Testverfahren unter Verwendung davon
ZA9710964B (en) Synthetic biepitope compounds which can be used as standards in the biological assays of troponin I
ATE323285T1 (de) Nicht-enzymatische methoden zur erzeugung von chemilumineszenz bei acridan-alkenen
DK1057021T3 (da) Fremgangsmåde til måling af totalanalyt